Sandborn WJ - Search Results

1

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.

Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. Sandborn WJ, et al. Gastroenterology. 2020 Feb;158(3):562-572.e12. doi: 10.1053/j.gastro.2019.08.027. Epub 2019 Aug 28. Gastroenterology. 2020. PMID: 31470005 Free article. Clinical Trial.

2

Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results.

Sandborn WJ. Sandborn WJ. Am J Gastroenterol. 1999 May;94(5):1161-71. doi: 10.1111/j.1572-0241.1999.01059.x. Am J Gastroenterol. 1999. PMID: 10235187 Review.

3

Intravenous azathioprine in severe ulcerative colitis: a pilot study.

Mahadevan U, Tremaine WJ, Johnson T, Pike MG, Mays DC, Lipsky JJ, Sandborn WJ. Mahadevan U, et al. Among authors: sandborn wj. Am J Gastroenterol. 2000 Dec;95(12):3463-8. doi: 10.1111/j.1572-0241.2000.03362.x. Am J Gastroenterol. 2000. PMID: 11151878 Clinical Trial.

4

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Sandborn WJ, et al. Gastroenterology. 2001 Nov;121(5):1088-94. doi: 10.1053/gast.2001.28674. Gastroenterology. 2001. PMID: 11677200 Clinical Trial.

5

Microscopic colitis: a review.

Pardi DS, Smyrk TC, Tremaine WJ, Sandborn WJ. Pardi DS, et al. Among authors: sandborn wj. Am J Gastroenterol. 2002 Apr;97(4):794-802. doi: 10.1111/j.1572-0241.2002.05595.x. Am J Gastroenterol. 2002. PMID: 12003412 Review.

6

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.

Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Sandborn WJ, et al. Gastroenterology. 2003 Aug;125(2):380-8. doi: 10.1016/s0016-5085(03)00877-1. Gastroenterology. 2003. PMID: 12891539 Clinical Trial.

7

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. Colombel JF, et al. Among authors: sandborn wj. Gastroenterology. 2004 Jan;126(1):19-31. doi: 10.1053/j.gastro.2003.10.047. Gastroenterology. 2004. PMID: 14699483

8

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Hanauer SB, et al. Among authors: sandborn wj. Am J Gastroenterol. 2005 Nov;100(11):2478-85. doi: 10.1111/j.1572-0241.2005.00248.x. Am J Gastroenterol. 2005. PMID: 16279903 Clinical Trial.

9

Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study.

Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Velayos FS, et al. Among authors: sandborn wj. Gastroenterology. 2006 Jun;130(7):1941-9. doi: 10.1053/j.gastro.2006.03.028. Gastroenterology. 2006. PMID: 16762617

10

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.

Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Kamm MA, et al. Among authors: sandborn wj. Gastroenterology. 2007 Jan;132(1):66-75; quiz 432-3. doi: 10.1053/j.gastro.2006.10.011. Epub 2006 Oct 12. Gastroenterology. 2007. PMID: 17241860 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

947 results

Search Page